Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Amibufenamide Long-term Follow-up in Chronic Hepatitis B
NCT06743438Phase 4Active, not recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir + amibufenamide in Chronic Hepatitis B (CHB), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Percentage of Participants with Serum HBV DNA Levels Below the Quantification Limit at Week (144+) 96. Started Mar 2022; status: active, not recruiting.
02
Drugs
tenofovir + amibufenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06743438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06743438.